نتایج جستجو برای: predictive biomarker
تعداد نتایج: 196512 فیلتر نتایج به سال:
We study information theoretic methods for ranking biomarkers. In clinical trials there are two, closely related, types of biomarkers: predictive and prognostic, and disentangling them is a key challenge. Our first step is to phrase biomarker ranking in terms of optimizing an information theoretic quantity. This formalization of the problem will enable us to derive rankings of predictive/progno...
Objectives Predictive biomarkers can be used to identify most suitable treatments for patients. To maximise patient benefit valid predictive biomarkers need to be used and several trial designs have been proposed to achieve this. We aimed to review the evidence considered sufficient by the European Medicines Agency (EMA) for inclusion of a predictive biomarker in a drug indication or contraindi...
preeclampsia is an important pregnancy disorder with serious maternal and fetal complications which its etiology has not been completely understood yet. early diagnosis and management of disease could reduce its potential side effects. the vascular endothelial growth factor (vegf) family including vegf-a is the most potent endothelial growth factor which induces angiogenesis and endothelial cel...
Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal METex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.
Improved understanding of cancer biology and advances in biotechnology bring us closer to the concept of personalized treatment of cancer. A key component of this new paradigm is development of biomarkers that can guide application of new and existing treatments. This requires a thorough understanding of the relationship between the biomarker and the treatment effect. Traditionally, most random...
The search for reliable biomarkers predictive of response to anti-VEGF therapy has been elusive. VEGF-A, the therapeutic target of bevacizumab, is an intuitive candidate as a predictive biomarker to bevacizumab-based anticancer therapy. However, there remains much controversy in the use of VEGF-A as a predictor of response to bevacizumab.
BACKGROUND Previously, we have examined the methylation status of SLC19A3 (solute carrier family 19, member 3) promoter and found that SLC19A3 was epigenetically down-regulated in gastric cancer. Here, we aim to develop a new biomarker for cancer diagnosis using methylated SLC19A3 DNA in plasma. METHODOLOGY/PRINCIPAL FINDINGS SLC19A3 gene expression was examined by RT-qPCR. Methylation status...
BACKGROUND The TORCH phase III trial compared the efficacy of first-line erlotinib followed by chemotherapy at progression (experimental arm) with the reverse sequence (standard arm) in unselected advanced non-small cell lung cancer (NSCLC) patients. Here we report biomarker analyses. METHODS EGFR and KRAS mutation, expression of EGFR family members and of cMET and PTEN and EGFR and ABCG2 ger...
Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal" mso-tstyle-rowband-size:0 mso-tstyle-colband-size:0 mso-style-noshow:yes mso-style-priority:99 mso-style-qformat:yes ms...
PURPOSE Prostate cancer aggressiveness and appropriate therapy are routinely determined following biopsy sampling. Current clinical and pathologic parameters are insufficient for accurate risk prediction leading primarily to overtreatment and also missed opportunities for curative therapy. EXPERIMENTAL DESIGN An 8-biomarker proteomic assay for intact tissue biopsies predictive of prostate pat...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید